Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



An Expanded Access Study of the Feasibility of Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients

Multiple Cancer Types

Hematologic, Leukemia, Lymphoma, Pediatric Leukemia, Pediatric Lymphoma, Pediatric Supportive Care, Pediatrics, Supportive Care
N/A
Kitko, Carrie
NCT01200017
VICCPED1619


Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Multiple Cancer Types

The primary objectives of this study are: Phase 1: To evaluate the safety of sequenced therapy with lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma and identify the most appropriate dose of lenzilumab for Phase 2. Phase 2: To evaluate the incidence of neurologic events with sequenced therapy given at the recommended Phase 2 dose (RP2D) of lenzilumab in participants with relapsed or refractory large B-cell lymphoma.
Lymphoma, Phase I
I/II
Oluwole, Olalekan
NCT04314843
VICCCTTP2024

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid / Round Cell Liposarcoma

Sarcoma

This is a study of genetically engineered ADP-A2M4 in HLA-A*02 subjects with metastatic or inoperable (advanced) Synovial Sarcoma or MRCLS who have received prior chemotherapy and whose tumor expresses the MAGE-A4 tumor antigen.
Sarcoma
II
Keedy, Vicki
NCT04044768
VICCSAR1948

Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed / Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Leukemia

The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed / refractory chronic lymphocytic leukemia (r / r CLL) and small lymphocytic lymphoma (r / r SLL).
Leukemia
I
Byrne, Michael
NCT03624036
VICCCTT18134

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed / Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed / Refractory B-Cell Non-Hodgkin Lymphoma

Pediatric Leukemia

The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed / refractory (r / r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r / r) B-cell non-Hodgkin lymphoma (NHL).
Pediatric Leukemia
I/II
Kitko, Carrie
NCT02625480
VICCPED15143

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Multiple Cancer Types

The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and / or cyclophosphamide, or ALLO-647 alone.
Multiple Myeloma, Phase I
I
Oluwole, Olalekan
NCT04093596
VICCCTTP1955

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: